- Home
- ELWS vs INTS Comparison
ELWS vs INTS Comparison
Compare ELWS & INTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ELWS
- INTS
- Stock Information
- Founded
- ELWS 2018
- INTS 2012
- Country
- ELWS Japan
- INTS United States
- Employees
- ELWS N/A
- INTS N/A
- Industry
- ELWS
- INTS Biotechnology: Pharmaceutical Preparations
- Sector
- ELWS
- INTS Health Care
- Exchange
- ELWS Nasdaq
- INTS Nasdaq
- Market Cap
- ELWS 12.1M
- INTS 12.2M
- IPO Year
- ELWS 2023
- INTS 2023
- Fundamental
- Price
- ELWS $3.19
- INTS $0.28
- Analyst Decision
- ELWS
- INTS Strong Buy
- Analyst Count
- ELWS 0
- INTS 4
- Target Price
- ELWS N/A
- INTS $4.50
- AVG Volume (30 Days)
- ELWS 182.1K
- INTS 2.5M
- Earning Date
- ELWS 09-30-2025
- INTS 11-12-2025
- Dividend Yield
- ELWS N/A
- INTS N/A
- EPS Growth
- ELWS N/A
- INTS N/A
- EPS
- ELWS N/A
- INTS N/A
- Revenue
- ELWS $3,083,071.00
- INTS N/A
- Revenue This Year
- ELWS N/A
- INTS N/A
- Revenue Next Year
- ELWS N/A
- INTS N/A
- P/E Ratio
- ELWS N/A
- INTS N/A
- Revenue Growth
- ELWS 145.52
- INTS N/A
- 52 Week Low
- ELWS $1.64
- INTS $0.19
- 52 Week High
- ELWS $10.50
- INTS $3.98
- Technical
- Relative Strength Index (RSI)
- ELWS 56.54
- INTS 56.44
- Support Level
- ELWS $2.60
- INTS $0.27
- Resistance Level
- ELWS $3.40
- INTS $0.30
- Average True Range (ATR)
- ELWS 0.32
- INTS 0.02
- MACD
- ELWS 0.09
- INTS 0.01
- Stochastic Oscillator
- ELWS 66.13
- INTS 78.69
About ELWS Earlyworks Co. Ltd.
Earlyworks Co Ltd is a blockchain-based technology company. It builds products, delivers services, and develops solutions based on a proprietary grid ledger system to leverage blockchain technology in various business settings, including advertisement tracking, online visitor management, and sales of non-fungible tokens. The company's customers represent a diverse range of industries, such as information technology, shipping, real estate, entertainment, cosmetics, and chemical products.
About INTS Intensity Therapeutics Inc. Common stock
Intensity Therapeutics Inc is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. The company leverages its DfuseRxtechnology platform to create new, proprietary drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Intensity's product candidates have the potential to induce an adaptive systemic immune response that not only attacks the injected tumor, but also non-injected tumors. Their pipeline is focused on realizing the full potential of INT230-6 in metastatic and local disease settings to help cancer patients with unmet medical need.